Designing of the Anticancer Nanocomposite with Sustained Release Properties by Using Graphene Oxide Nanocarrier with Phenethyl Isothiocyanate as Anticancer Agent
Dasan Mary Jaya Seema,
Bullo Saifullah,
Mariadoss Selvanayagam,
Sivapragasam Gothai,
Mohd Zobir Hussein,
Suresh Kumar Subbiah,
Norhaizan Mohd Esa,
Palanisamy Arulselvan
Affiliations
Dasan Mary Jaya Seema
Department of Advanced Zoology and Biotechnology, Loyola Institute of Frontier Energy (LIFE), Loyola College, Chennai 600034, India
Bullo Saifullah
Material Synthesis and characterization laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang 43400, Malaysia
Mariadoss Selvanayagam
Department of Advanced Zoology and Biotechnology, Loyola Institute of Frontier Energy (LIFE), Loyola College, Chennai 600034, India
Sivapragasam Gothai
Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia
Mohd Zobir Hussein
Material Synthesis and characterization laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang 43400, Malaysia
Suresh Kumar Subbiah
Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia
Norhaizan Mohd Esa
Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia
Palanisamy Arulselvan
Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia
In this study anticancer nanocomposite was designed using graphene oxide (GO) as nanocarrier and Phenethyl isothiocyanate (PEITC) as anticancer agent. The designed formulation was characterized in detailed with XRD, Raman, UV/Vis, FTIR, DLS and TEM etc. The designed anticancer nanocomposite showed much better anticancer activity against liver cancer HepG2 cells compared to the free drug PEITC and was also found to be nontoxic to the normal 3T3 cells. In vitro release of the drug from the anticancer nanocomposite formulation was found to be sustained in human body simulated phosphate buffer saline (PBS) solution of pH 7.4 (blood pH) and pH 4.8 (intracellular lysosomal pH). This study suggests that GO could be developed as an efficient drug carrier to conjugate with PEITC for pharmaceutical applications in cancer chemotherapies.
